![FDA Greenlights Enhertu for Advanced HER2-Positive Tumors – The Babak Lab](https://oncodaily.com/pub/uploads/2024/03/32681d3d-0c83-49e8-91ea-cef712176d6a-1280x720.jpeg)
FDA Greenlights Enhertu for Advanced HER2-Positive Tumors – The Babak Lab
Maria Babak shared a post by
“Incredible news for the oncology community and patients everywhere! The FDA’s accelerated approval of Enhertu is a game-changer for those battling unresectable or metastatic HER2-positive tumors.
This innovative treatment brings new hope and possibilities for patients who previously had limited treatment options. Congratulations to all involved in making this breakthrough possible!”
Quoting
“Clinical Monday: FDA Greenlights Enhertu for Advanced HER2-Positive Tumors!
Source: Maria Babak/LinkedIn and The Babak Lab/LinkedIn
Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. She earned her Ph.D. in bioinorganic chemistry from the University of Vienna in 2014. From 2015 to 2020, Dr. Babak was a postdoctoral research fellow at the National University of Singapore under the mentorship of Prof.
Wee Han Ang, where she developed a strong passion for drug discovery and drug target identification. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.
Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.